| |
(new Study) Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 (pan-genotypic protease) in Subjects With Chronic Hepatitis C Virus Infection
|
| |
| |
.....https://clinicaltrials.gov/ct2/show/NCT02185794
This study will evaluate the safety, tolerability, and antiviral activity of GS-9857 in adults with genotypes 1, 2, 3, or 4 hepatitis C virus (HCV) infection. GS-9857 will be administered daily for 3 consecutive days. All participants will be monitored for up to 48 weeks after last dose to monitor for persistence of viral mutations.
|
|
| |
| |
|
|
|
